Polyamines are organic cations found in all eukaryotic cells and intimately involved in, and required for, distinct biological functions. An increasing body of evidence indicates that the regulation of cellular polyamines is a central convergence point for the multiple signaling pathways driving various cellular functions. Over the last decade, considerable progress has been made in und- standing the molecular functions of cellular polyamines. These significant findings provide a fundamental basis to not only define the exact role of polyamines in physiology, but also to develop new therapeutic approaches for cancers and other diseases. The major objective of this book is to provide a timely and long lasting guide for investigators in the fields of polyamines, physiology, pharmacology, and cancer research. It will provide a foundation based on research and address the potential for subsequent applications in clinical practice. Polyamine Cell Signaling: Physiology, Pharmacology, and Cancer Research is divided into four main parts: Part I: Polyamines in Signal Transduction of Cell Proliferation Part II: Polyamines in Cellular Signaling of Apoptosis, Carcinogenesis, and Cancer Therapy Part III: Polyamines in Cell Motility and Cell-Cell Interactions Part IV: Polyamine Homeostasis and Transport This book not only covers the current state-of-the-art findings relevant to cellular and molecular functions of polyamines, but also provides the underlying conceptual basis and knowledge regarding potential therapeutic targeting of polyamines and polyamine metabolism. These points are addressed by int- nationally recognized experts in their contributions to this book.

This third and final volume in the "Ion Transport in Tumor Biology" collection presents novel diagnostic and therapeutic approaches in cancer based on the exploitation of ion transport proteins. The authors critically examine several transportome members, particularly Na+, K+, Ca2+, and Cl- channels, as well as organic solute carriers regarding their suitability as therapeutic targets. Synergistic effects resulting from the combined use of classical cytostatics with ion transport-inhibiting drugs are pointed out, and the capability of bispecific antibodies to function as anticancer drugs is discussed. As readers will also learn, the use of ion channel inhibitors could improve the outcome of radiotherapy because the development of radio-resistance during radiotherapeutic treatment often correlates with increases in the expression levels and conductance of ion channels. The translational topics of this volume form a bridge between biochemical research and therapeutic application. As part of a three-volume collection, this book will fascinate members of the active research community, as well as clinicians in the cancer field.

The Ninth Annual Pezcoller Symposium entitled "The Biology of Tumors" was held in Rovereto, Italy, June 4-7, 1997. It focused on the genetic mechanisms underlying het erogeneity of tumor cell populations and tumor cell differentiation, on interactions be tween tumor cells and cells of host defenses, and the mechanisms of angiogenesis. With presentations at the cutting edge of progress and stimulating discussions, this symposium addressed issues related to phenomena concerned with cell regulation and cell interactions as determined by activated genes through the appropriate and timely media tion of gene products. Important methodologies that would allow scientists to measure dif ferentially genes and gene products and thus validate many of the mechanisms of control currently proposed were considered, as were the molecular basis of tumor recognition by the immune system, interactions between cells and molecular mechanisms of cell regula tion as they are affected by or implemented through these interactions. The molecular and cellular mechanisms of tumor vascularization were also discussed. It was recognized that angiogenesis provides a potential site of therapeutic intervention and this makes it even more important to understand the mechanisms underlying it. We wish to thank the participants in the symposium for their substantial contribu tions and their participation in the spirited discussions that followed. We would also like to thank Drs."

Where do you begin to look for a recent, authoritative article on the diagnosis or management of a particular malignancy? The few general oncology textbooks are generally out of date. Single papers in specialized journals are informative, but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfor tunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of authoritative volumes that aim to meet this need. It is an attempt to establish a critical mass of oncology literature covering virtually all oncology topics, which is revised frequently to keep the coverage up to date, and which is easily available on a single library shelf or by a single personal subscription. We have approached the problem in the following fashion: first, by dividing the oncology literature into specific subdivisions, such as lung can cer, genitourinary cancer, pediatric oncology, etc.; and second, by asking eminent authorities in each of these areas to edit a volume on the specific topic on an annual or biannual basis. Each topic and tumor type is covered in a volume appearing frequently and predictably, discussing current diag nosis, staging, markers, all forms of treatment modalities, basic biology, and more."

PET in Clinical Oncology describes the use of Positron Emission Tomography (PET) in the diagnosis and management of malignant tumors. Experts from Germany and the United States present basics, technical details, and clinical aspects for both standard and new PET techniques. The book illustrates the importance of PET in comparison to other imaging techniques.
Generously supplemented with charts, tables, and illustrations, each chapter provides the reader with well-delineated descriptions, from the basic technical situation through the clinical use of PET. This book is helpful to all those dealing with the diagnosis and therapy of cancer.

Interest in angiogenesis research remains strong in recent years and exciting new discoveries, about modulators of angiogenesis, their receptors, the transduction mechanisms and the angiogenic genes involved, have contributed to our present day understanding of this complex process. This knowledge has provided the basis and broadened the scope of angiogenesis - based therapy in oncology and many other clinical conditions. This monograph contains the contributions to the NATO Advanced Study Institute on "Angiogenesis: Models, Modulators and Clinical Applications," which was held in Rhodes, Greece, from June 20-30, 1997. This was the fourth of a series of NATO supported international meetings on Angiogenesis aiming to bring together basic scientists with clinicians to exchange ideas, disseminate new knowledge and discuss the present status and potential new directions in this fast moving area of biomedical research. The International Organising Committee that included Drs. E. Dejana, C Haudenschild, M. Hackel, H. Kleinman, P. Lelkes, M. Presta, P. Polverini, D. Thompson, has provided invaluable help with their insightful suggestions in the formulation of the scientific program for which I am grateful. I wish to thank all the participants for their enthusiastic participation and their complimentary comments on the success of the conference.

Capsaicin is a principal pungent ingredient of red chili peppers, first isolated in the early nineteenth century by Christian Friedrich Bucholz. Widely consumed as a spice in South Asia and Latin America, Capsaicin has been used to treat pain and inflammation associated with a variety of diseases, including rheumatoid arthritis, diabetic neuropathy, post-masectomy pain, cluster headaches, and herpes zoster. Although recent studies have evaluated capsaicin as a novel anti-cancer agent, and mechanisms of capsaicin in preventing cancer have been described sporadically, the literature lacks a comprehensive review of capsaicin as a chemo-preventive agent. Role of Capsaicin in Oxidative Stress and Cancer offers a thorough exploration of the preventive and therapeutic effects of capsaicin in cancer models such as melanoma, pancreatic cancer, colon cancer, gastric cancer, breast cancer, prostate cancer, skin cancer, lung cancer, multiple myeloma and glioma. The contributors, all internationally recognized researchers, identify various molecular and cellular targets of capsaicin, and show the critical role of mitochondria in capsaicin-mediated therapeutic effects. Readers will learn how capsaicin prevents or may treat cancer, how different cells respond to capsaicin, how environmental carcinogen-induced carcinogenesis can be prevented by capsaicin and the mechanism of oxidative stress caused by capsaicin. This book will benefit medical students, oncologists and cancer researchers everywhere.

Cancer victims are bombarded with misleading information about alternative medicine. Many such treatments try to sell false hope at inflated prices, and many promise a cure without side-effects. This book explains why alternative cancer cures are a fallacious concept. However, it also outlines the important role of alternative medicine in supporting cancer patients and improving their quality of life.

Twenty years ago when Children's Cancer Association of Japan was born, the diagnosis of childhood leukemia amounted to a death sentence. Only 20% or so of children with leukemia survived more than 5 years. Since then, enormous improvements have been achieved regarding our understanding on the etiology, diagnosis, and the treatment of childhood leukemia. Now, 70% of children with leukemia survive and enter adult life. Even though the improved survival rate of children with leukemia represents a medical success story, we now face new problems. The first problem is the fact that we still lose 20-30% of patients with childhood leukemia. To address this problem, we need to understand the etiology, epidemiology, and biology of leukemia; to identify the patients at greater risk; and to develop adequate treatments. The second problem is the treatment itself. Even though efficacious, the modem treatment for leukemia is a grueling experience for children and their families. We should develop a total care system for families and children based on a deep understanding of their needs. The third problem is the aftereffects of the treatment and of cured leukemia. Extensive radiation and chemotherapy have an entirely different spectrum of long-term effects on children than on adults. These treatments in the early stage of life, when the mind and body are developing, create many physical and psychological problems. These are the present problems of childhood leukemia.

Clinical trials have two purposes -- to treat the patients in the trial, and to obtain information which increases our understanding of the disease and especially how patients respond to treatment. Statistical design provides a means to achieve both these aims, while statistical data analysis provides methods for extracting useful information from the trial data. Recent advances in statistical computing have enabled statisticians to implement very rapidly a broad array of methods which previously were either impractical or impossible. Biostatisticians are now able to provide much greater support to medical researchers working in both clinical and laboratory settings. As our collective toolkit of techniques for analyzing data has grown, it has become increasingly difficult for biostatisticians to keep up with all the developments in our own field. Recent Advances in Clinical Trial Design and Analysis brings together biostatisticians doing cutting-edge research and explains some of the more recent developments in biostatistics to clinicians and scientists who work in clinical trials.

Primary lung tumors are now a global health problem. The incidence has risen dramatically during the last 5--6 decades, reflecting the popularity of cigarette smoking. In this, the fifth volume dealing with lung cancer in the series KappaCANCER TREATMENT AND RESEARCHkappa, many current research topics are covered by notable authorities, including chemoprevention, growth factors, multidrug resistance, new agents, and haematopoietic growth factors. Altogether, the 17 chapters from twelve countries highlight some of the rapid developments taking place in basic and clinical research of lung cancer. These chapters not only give up-to-date information, they will also stimulate further research into this man-made disease which was almost unheard of a century ago.

This volume explores pericytes' roles under distinct pathological conditions, ranging from tumors, ALS, Alzheimer's disease, Multiple Sclerosis, stroke, diabetes, atherosclerosis, muscular dystrophies and more. Together with its companion volumes Pericyte Biology in Different Organs and Pericyte Biology - Novel Concepts, Pericyte Biology in Disease presents a comprehensive update on the latest information and most novel functions attributed to pericytes. To those researchers newer to this area, it will be useful to have the background information on these cells' unique history. It will be invaluable for both advanced cell biology students as well as researchers in cell biology, stem cell biology and clinicians involved with these specific diseases.

This textbook discusses the systemic consequences of cancer, covering a range of topics from tumor-promoting systemic effects to the development of cachexia, as summarized in the introductory chapter 1. Part I of this textbook focuses on tumor-promoting systemic effects and begins with a chapter on how tumor-derived extracellular vesicles and particles lay the foundation for future metastases (Chapter 2). Chapter 3 discusses how metastatic cells that have colonized the bone impact the local bone microenvironment, neighboring muscles, and host physiology. Chapter 4 summarizes the available strategies for targeting metastatic cancer and emphasizes the need to incorporate a systemic view of the disease. Following this overview of the systemic effects of cancer progression, Part II of the textbook discusses cancer-induced cachexia, a debilitating systemic effect of advanced cancer. Chapters 5-7 examine the key signaling pathways (interleukin-6/GP130, NF-kB, and muscle proteolysis) that drive the development of cancer cachexia. Chapters 8 and 9 in Part III of this textbook explore how toxicities from anti-cancer therapy are associated with the onset of cachexia in cancer patients, and provide insight into potential approaches to simultaneously target both cancer and cachexia. Chapters 10 and 11 (Part IV) conclude this textbook by outlining promising approaches for the diagnosis and treatment of cachexia as well as strategies to prevent the development of cachexia through exercise. An understanding of the systemic effects of cancer is essential for the design of effective anti-cancer and anti-cachexia treatment strategies. As such, this textbook provides key information for both students and scientists engaged in cancer research and oncology.

Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is also included.

Comprehensive, authoritative, and up to date, Oncologic Imaging: A Multidisciplinary Approach, 2nd Edition, covers every aspect of radiographic imaging for the diagnosis, treatment, and management of the cancer patient. Dr. Paul M. Silverman and an expert author team from MD Anderson Cancer Center provide all the current, practical information available, while incorporating their unique experience based upon extensive, daily clinical care of patients with cancer. In one convenient volume, this definitive, one-of-a-kind text discusses new diagnostic imaging and surgical approaches as well as therapeutic cutting-edge treatments from radiation and medical oncology, focusing on best practices and the newest standards for personalized medicine. Brings together a unique multidisciplinary team of authors including clinical radiologists, medical oncologists, radiation oncologists, and surgical oncologists who reflect team-based practice. Features an all-new chapter on head and neck imaging, authored by world experts in this complex area. Contains extensive updates throughout, including transformational state-of-the-art imaging modalities such as PET/CT, and the full range of traditional modalities, including multidetector CT (MDCT), ultrasound, and MR in conjunction with the latest advances in genetics, molecular oncology, and targeted therapies. Distills practical, up-to-date information into a concise and consistent format with key point summaries, algorithms, clear drawings, and full-color staging diagrams. Includes emerging options for care based on practice recommendations and evidence in the literature. Provides updated tumor staging information based on the AJCC Classification of Malignant Tumors, 8th edition. Highlights the text with 1,000 high-quality radiographic images: CT, MR, hybrid imaging (PET/CT, PET/MR), mammography, and ultrasound, as well as clear line anatomic drawings, graphs, and algorithms. Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor Immunoenvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions.

This book illustrates the importance of the Natural Biometabolites, which offer a rich reservoir of candidate compounds for drug discovery in the battle against cancer. Recent research and development efforts concerning anti-cancer drugs derived from natural products have led to the identification of numerous candidate molecules that inhibit cancer cell proliferation and metastasis using a variety of mechanisms. Given its scope, the book offers a valuable resource for cancer biologists and general oncologists alike, while also benefitting research professionals in Science, Nursing, Medicine, Biochemistry, Genetics and Bioscience who wish to understand the fundamentals of prognosis and prediction in tumorigenesis. Moreover, the book provides an essential platform for understanding drug resistance mechanisms and combatting the growing menace of multidrug resistance.

An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.

This book presents unique compendium of groundbreaking ideas where scientists from many different backgrounds are united in their interest in interdisciplinary approaches towards origins and development of cancers, innovative ways of searching for cancer treatment and the role of cancer in the evolution. Chapters give an unequivocal slice of all areas that relate to a quest for understanding cancer and its origin as many-fold nonlinear system, complexity of the cancer developments, a search for cancer treatment using artificial intelligence and evolutionary optimisation, novel modelling techniques, molecular origin of cancer, the role of cancer in evolution of species, interpretation of cancer in terms of artificial life and artificial immune systems, swarm intelligence, cellular automata, computational systems biology, genetic networks, cellular computing, validation through in vitro/vivo tumour models and tumour on chip devices. The book is an inspiring blend of theoretical and experimental results, concepts and paradigms. Distinctive features The book advances widely popular topics of cancer origin, treatment and understanding of its progress The book is comprised of unique chapters written by world top experts in theoretical and applied oncology, complexity theory, mathematics, computer science. The book illustrates attractive examples of mathematical and computer models and experimental setups.

This book discusses the mechanisms leading to immune-mediated tissue rejection following the hypothesis that independent of the disease process the final effector mechanism is shared by most (but not all) pathologies and it is relatively simple. The book covers evidence gathered to support the thesis by studies performed in humans during rejection or in experimental models and will focus particularly (but not exclusively) on the analysis of the rejected tissue rather than the systemic circulation. Several disease processes are discussed including example of chronic inflammatory process without resolution of the pathologic process and acute one with resolution of the pathologic process (clearance of pathogen, rejection of tumor) or unwanted tissue destruction (allograft rejection, autoimmunity).

Cancer Informatics: Essential Technologies for Clinical Trials describes the National Cancer Institute¿s vision of a Cancer Informatics Infrastructure (CII). By exploiting the best that the Internet and information technology have to offer, the CII will facilitate clinical trials, for all who are involved, including the patient along with the myriad of health professionals involved in cancer trials. To bridge the chasm between discoveries and best clinical practices, the editors describe the CII and how it can function to expedite the clinical trial life cycle, facilitate faster and safer drug development, and make more appropriate treatment choices available to cancer patients. Presented in four comprehensive sections edited by leading experts, the book highlights: ¿ E-commerce ¿ Digital libraries ¿ Standards development ¿ Public health informatics ¿ Common data elements (CDEs) ¿ Clinical trials information systems ¿ Consumer education and support Cancer Informatics: Essential Technologies for Clinical Trials is an indispensable guide to clinical trials. Its contributors speak to oncologists and primary care physicians, as well as researchers, trial managers, administrators, informaticians, and consumers. Today, science is extending our knowledge of genes, proteins, and pathways, and pharmaceutical companies are developing more and more new therapies. In this rapidly changing world, the technologies that cancer informatics provides are essential to efforts to translate cancer research into cancer care, control, and, ultimately, prevention. John S. Silva, M.D., Center for Bioinformatics, National Cancer Institute Marion J. Ball, Ed.D., Vice President, Clinical Solutions, Healthlink, Inc.; Adjunct Professor, The Johns Hopkins University School of Nursing Christopher G. Chute, M.D., Dr.P.H., Professor of Medical Informatics, Head, Section of Medical Information Resources, Mayo Clinic Judith V. Douglas, M.A., M.H.S., formerly Associate, First Consulting Group Curtis P. Langlotz, M.D., Ph.D., Assistant Professor of Radiology, Epidemiology, and Computer and Information Science, University of Pennsylvannia Joyce. C. Niland, Ph.D., Chair, Division of Information Sciences, Director, Department of Biostatistics, City of Hope National Medical Center William L. Scherlis, Ph.D., Principal Research Scientist, School of Computer Science, Carnegie Mellon University

More often than not, progress in medicine occurs incrementally. The report of an 'important' new observation is typically greeted by a mixture of excitement and skepticism. Yet the true value of the discovery may not be known for several years until it is confirmed (or refuted) by independently conducted studies. In some cases, controversy may continue to shroud a topic due to the discordant results generated by different research groups. Since the last Gynecologic Oncology volume in the Cancer Treatment and Research series, a number of new areas have emerged that shed new light on the pathogenesis, diagnosis, and treatment of gynecologic malignancies. In this volume of the Cancer Treatment and Research series, I have attempted to integrate articles that highlight some of these newest developments with chapters that provide an overview of selected areas of controversy. This volume is not meant to be an abbreviated text of gynecologic oncology but rather a collection of selected works that can provide the reader with a better perspective on the areas of change within the field. The application of molecular biology to cervical cancer has allowed us to understand more completely the roles of human papilloma viruses and cellular oncogenes in the development of cancer of the uterine cervix.

Our recent understanding of the cellular and molecular defects and the regulation of the apoptotic signalling pathways has resulted in rationally designed anticancer strategies and the development of novel agents that regulates apoptosis. A comprehensive review of all apoptotic-related anticancer therapies is not the purpose of this book. However, in the volume of this book with 11 chapters, we have described a number of novel apoptotic regulators that have shown promising value and also great feasibility for cancer treatment. These novel agents either occur naturally or are chemically synthesized. While we are excited about the discovery and development of these novel apoptotic regulators as potential anticancer agents, a degree of caution should be always borne in mind when interpreting the success of preclinical pro-apoptotic candidates since potential problems inevitably lie ahead. These problems usually include target specificity, unanticipated toxicity, compound stability, formulation issues, pharmacokinetic and pharmacodynamic profiles. Nevertheless, we believe that this collection of 11 chapters by established leaders in the area of apoptosis will be of great interest to not only academics working in the field of cancer research and apoptosis but also pharmaceutical and pharmacological industries that . We are looking forward to the further development to push these potential agents toward clinical stage.

The fifth Annual Pezcoller Symposium entitled, Apoptosis, was held in Trento, Italy, June 9-1I, 1993 and was focused on the specific phenomena leading to Programmed Cell Death (PCD) or Apoptosis, and the mechanisms involved. With presentations at the cutting edge of progress and stimulating discussions, this Symposium addressed the genetics and molecular mechanisms determining PCD and the role of this suicidal process in cancer and the immune system. The functions of pS3, c myc and bel 2 in affecting apoptosis in different cell types and the role of ions and intracellular pH changes and that of intranuelear endonueleases are given particular emphasis as are the effects of anticancer agents, hormone imbalances and growth factors. The role of pS3, a tumor suppressor gene, in inducing PCD is discussed in detail as pertinent to hematological and non-hernatological tumors. The requirement of pS3 for the induction ofapoptosis by ionizing radiation or adenovirus oncoproteins is outlined. Decision points during the cell cyele affecting the cascade ofevents leading to PCD are discussed as is their role as "switches" under the control of c-myc and bel-2 proteins or the influence of cyele specific drugs. The concurrent requirement of multiple signals in determining apoptosis is emphasized. The examples of the role of PCD in the regulation of hematopoiesis, and in the generation of antigen-specific immune repertoire are illustrated.

In the recent years, a significant amount of research has emerged connecting the link between alcohol and cancer. The field has rapidly advanced, especially since the complex connection between alcohol and cancer has several unique sub areas that are being investigated. This proceedings volume will contain chapters based upon the presentation of the 2nd International Conference on Alcohol and Cancer in Colorado, 2013. The various topics explore the affects of alcohol on: liver and breast cancer; cell signaling and cancer; stem cells; biomarkers and metabolomics; aerodigestive cancers; cancer and the immune system and more.